Literature DB >> 9337208

Myocardial 99mTc-tetrofosmin uptake during adenosine-induced vasodilatation with either a critical or mild coronary stenosis: comparison with 201Tl and regional myocardial blood flow.

D K Glover1, M Ruiz, J Y Yang, W H Smith, D D Watson, G A Beller.   

Abstract

BACKGROUND: Clinical studies have shown a comparable coronary stenosis detection rate between 99mTc-tetrofosmin and 201Tl but with smaller defect magnitudes for 99mTc-tetrofosmin. The goals of this study were to measure the first-pass extraction fraction (EF) of 99mTc-tetrofosmin in canine myocardium and to compare 99mTc-tetrofosmin with 201Tl uptake during adenosine-induced vasodilatation in dogs with various degrees of coronary stenosis. METHODS AND
RESULTS: EF was calculated in 4 anesthetized, open-chest dogs after intracoronary administration of 125I-labeled albumin and 99mTc-tetrofosmin. In another 16 dogs with either critical (n=6) or mild (n= 10) left anterior descending coronary artery (LAD) stenoses, 201Tl and 99mTc-tetrofosmin were administered during adenosine infusion (250 microg x kg(-1) x min(-1)). Dogs were killed 5 minutes later, and tracer activities were determined by ex vivo imaging of heart slices and by well counting. Mean 99mTc-tetrofosmin EF was 54.0+/-3.7%. In the 6 critical-stenosis dogs, the LAD-to-left circumflex artery (LCx) microsphere flow ratio was 0.22+/-0.02 with adenosine. The LAD-to-LCx activity ratios were 0.37+/-0.04 for 201Tl and 0.67+/-0.05 for 99mTc-tetrofosmin (P<.01). For the 10 mild-stenosis dogs, the LAD-to-LCx flow ratio was 0.44+/-0.05. The 201Tl activity ratio was 0.58+/-0.04, compared with 0.81+/-0.04 for 99mTc-tetrofosmin (P<.01). Thus, in both groups, 99mTc-tetrofosmin uptake underestimated the flow disparity more than 201Tl. Similarly, magnitudes of ex vivo image defects were significantly greater for 201Tl than for 99mTc-tetrofosmin in both groups.
CONCLUSIONS: In this canine model, relative underperfusion with adenosine stress is better resolved with 201Tl than with 99mTc-tetrofosmin and may be explained by the lower EF for 99mTc tetrofosmin. With clinical imaging, greater 201Tl attenuation and redistribution may lessen this advantage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9337208     DOI: 10.1161/01.cir.96.7.2332

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  30 in total

1.  Diagnostic and prognostic applications for vasodilator stress myocardial perfusion imaging and the importance of radiopharmaceutical selection.

Authors:  R C Hendel
Journal:  J Nucl Cardiol       Date:  2001 Jul-Aug       Impact factor: 5.952

Review 2.  Comparison of Tl-201 with Tc-99m-labeled myocardial perfusion agents: technical, physiologic, and clinical issues.

Authors:  P Kailasnath; A J Sinusas
Journal:  J Nucl Cardiol       Date:  2001 Jul-Aug       Impact factor: 5.952

Review 3.  Myocardial perfusion imaging agents: SPECT and PET.

Authors:  George A Beller; Steven R Bergmann
Journal:  J Nucl Cardiol       Date:  2004 Jan-Feb       Impact factor: 5.952

Review 4.  Diagnosis of coronary artery disease by radionuclide myocardial perfusion imaging.

Authors:  C Y Loong; C Anagnostopoulos
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

5.  Novel SPECT perfusion imaging agents with improved myocardial or liver kinetics: experimental studies and the need for clinical evaluation.

Authors:  Laurent M Riou; Alexis Broisat
Journal:  J Nucl Cardiol       Date:  2010-10       Impact factor: 5.952

6.  Accuracy of stress Tc-99m tetrofosmin myocardial perfusion tomography for the diagnosis and localization of coronary artery disease in women.

Authors:  Abdou Elhendy; Arend F L Schinkel; Jeroen J Bax; Ron T van Domburg; Roelf Valkema; Elena Biagini; Harm H Feringa; Don Poldermans
Journal:  J Nucl Cardiol       Date:  2006-09       Impact factor: 5.952

7.  (99m)Tc-tetrofosmin as a prognostic agent?

Authors:  Ichiro Matsunari; Junichi Taki; Kenichi Nakajima; Norihisa Tonami
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01       Impact factor: 9.236

8.  Tc-99m N-NOET: Chronicle of a unique perfusion imaging agent and a missed opportunity?

Authors:  Gérald Vanzetto; Daniel Fagret; Catherine Ghezzi
Journal:  J Nucl Cardiol       Date:  2004 Nov-Dec       Impact factor: 5.952

9.  Journey to find the ideal PET flow tracer for clinical use: are we there yet?

Authors:  David K Glover; Robert J Gropler
Journal:  J Nucl Cardiol       Date:  2007 Nov-Dec       Impact factor: 5.952

10.  Assessment of myocardial perfusion with Tc-99m: image is everything.

Authors:  Seth T Dahlberg
Journal:  J Nucl Cardiol       Date:  2009-04-30       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.